Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > FDA Says Genta May Resume Clinical Trial of Tesetaxel

Washington Drug Letter

June 30, 2008 | Vol. 40 No. 26

FDA Says Genta May Resume Clinical Trial of Tesetaxel

Genta has received notification from the FDA that it may resume clinical trials with its oncology drug tesetaxel.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Genentech’s Phase II Trial Promising for Pertuzumab Combo in Breast Cancer Amgen: Denosumab Superior to Zometa in Advanced Breast Cancer Patients FDA Lifts Partial Clinical Hold on Genmab Cancer Drug FDA Lifts Clinical Hold on Tesetaxel

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.